JP2006524252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524252A5 JP2006524252A5 JP2006513151A JP2006513151A JP2006524252A5 JP 2006524252 A5 JP2006524252 A5 JP 2006524252A5 JP 2006513151 A JP2006513151 A JP 2006513151A JP 2006513151 A JP2006513151 A JP 2006513151A JP 2006524252 A5 JP2006524252 A5 JP 2006524252A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- phenyl
- alkyl
- hydrogen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- -1 perfluoromethoxy Phenyl Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000010706 fatty liver disease Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- FXIOMELBXCQVRK-UHFFFAOYSA-N ethyl 6-[3-[(2,6-dimethylphenyl)methoxy]phenyl]hex-5-enoate Chemical compound CCOC(=O)CCCC=CC1=CC=CC(OCC=2C(=CC=CC=2C)C)=C1 FXIOMELBXCQVRK-UHFFFAOYSA-N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 208000003790 Foot Ulcer Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- LPBWCFBFSQKSQQ-UHFFFAOYSA-N ethyl 5-[3-[(2,6-dimethylphenyl)methoxy]phenyl]pent-4-enoate Chemical group CCOC(=O)CCC=CC1=CC=CC(OCC=2C(=CC=CC=2C)C)=C1 LPBWCFBFSQKSQQ-UHFFFAOYSA-N 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- SRJHZFWVHPERTN-UHFFFAOYSA-N 5-[3-[(2,6-dimethylphenyl)methoxy]phenyl]pent-4-enoic acid Chemical group CC1=C(COC=2C=C(C=CC=2)C=CCCC(=O)O)C(=CC=C1)C SRJHZFWVHPERTN-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46455303P | 2003-04-22 | 2003-04-22 | |
| US60/464,553 | 2003-04-22 | ||
| PCT/US2004/012142 WO2004093806A2 (en) | 2003-04-22 | 2004-04-20 | Compounds for the treatment of metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006524252A JP2006524252A (ja) | 2006-10-26 |
| JP2006524252A5 true JP2006524252A5 (enExample) | 2007-06-14 |
| JP4697973B2 JP4697973B2 (ja) | 2011-06-08 |
Family
ID=33310913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513151A Expired - Fee Related JP4697973B2 (ja) | 2003-04-22 | 2004-04-20 | 代謝障害の処置のための化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7361686B2 (enExample) |
| EP (1) | EP1618086B1 (enExample) |
| JP (1) | JP4697973B2 (enExample) |
| CN (1) | CN1777576A (enExample) |
| AT (1) | ATE450496T1 (enExample) |
| CA (1) | CA2521589C (enExample) |
| DE (1) | DE602004024382D1 (enExample) |
| WO (1) | WO2004093806A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20033394A3 (cs) * | 2001-06-12 | 2005-03-16 | Wellstat Therapeutics Corporation | Sloučeniny pro léčení metabolických poruch a způsob jejich přípravy |
| EP2266946A3 (en) * | 2003-02-13 | 2012-12-12 | Wellstat Therapeutics Corporation | Compound For The Treatment Of Metabolic Disorders |
| DE602004030004D1 (de) * | 2003-04-15 | 2010-12-23 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
| EP1617835B1 (en) * | 2003-04-30 | 2011-09-28 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CN1835743A (zh) * | 2003-08-20 | 2006-09-20 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| US8022249B2 (en) * | 2005-04-01 | 2011-09-20 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| CA2636290A1 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| WO2007087504A2 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP1976377A4 (en) * | 2006-01-25 | 2010-06-23 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| EP1978948A4 (en) * | 2006-02-02 | 2010-06-16 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER |
| CA2637884A1 (en) * | 2006-02-13 | 2007-08-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| JP2009528375A (ja) * | 2006-02-28 | 2009-08-06 | ウェルスタット セラピューティクス コーポレイション | 代謝障害を処置するための化合物 |
| AU2007235145B2 (en) * | 2006-03-31 | 2011-09-22 | Wellstat Therapeutics Corporation | Combination treatment of metabolic disorders |
| WO2007137008A2 (en) * | 2006-05-18 | 2007-11-29 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US20100234464A1 (en) * | 2006-06-09 | 2010-09-16 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US8481595B2 (en) * | 2008-01-15 | 2013-07-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US8664433B2 (en) * | 2008-05-05 | 2014-03-04 | Wellstat Therapeutics Corporation | Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid |
| WO2010053910A1 (en) | 2008-11-04 | 2010-05-14 | Wellstat Therapeutics Corporation | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3419952A1 (de) | 1984-05-28 | 1985-11-28 | Bayer Ag, 5090 Leverkusen | Substituierte phenoxyphenylpropionsaeure-derivate |
| DE3621775A1 (de) | 1986-03-13 | 1988-01-07 | Thomae Gmbh Dr K | Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US4897397A (en) * | 1988-12-16 | 1990-01-30 | Schering Corporation | Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents |
| US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
| WO1995004025A1 (en) | 1993-07-29 | 1995-02-09 | Chugai Seiyaku Kabushiki Kaisha | Tricarboxylic acid derivative having squalene synthetase inhibitor activity |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| JP3880108B2 (ja) * | 1994-11-02 | 2007-02-14 | 武田薬品工業株式会社 | ２，４−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物 |
| TW403748B (en) * | 1994-11-02 | 2000-09-01 | Takeda Chemical Industries Ltd | An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same |
| US7238716B2 (en) | 2000-12-28 | 2007-07-03 | Takeda Pharmaceuticals Company Limited | Alkanoic acid derivatives process for their production and use thereof |
| JP4148681B2 (ja) * | 2000-12-28 | 2008-09-10 | 武田薬品工業株式会社 | アルカン酸誘導体、その製造法および用途 |
| CZ20033394A3 (cs) * | 2001-06-12 | 2005-03-16 | Wellstat Therapeutics Corporation | Sloučeniny pro léčení metabolických poruch a způsob jejich přípravy |
| AU2003286728A1 (en) * | 2002-11-01 | 2004-06-07 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP2266946A3 (en) * | 2003-02-13 | 2012-12-12 | Wellstat Therapeutics Corporation | Compound For The Treatment Of Metabolic Disorders |
| DE602004030004D1 (de) | 2003-04-15 | 2010-12-23 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
| EP1617835B1 (en) * | 2003-04-30 | 2011-09-28 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
-
2004
- 2004-04-20 US US10/553,936 patent/US7361686B2/en not_active Expired - Lifetime
- 2004-04-20 EP EP04750364A patent/EP1618086B1/en not_active Expired - Lifetime
- 2004-04-20 DE DE602004024382T patent/DE602004024382D1/de not_active Expired - Lifetime
- 2004-04-20 CN CNA2004800107323A patent/CN1777576A/zh active Pending
- 2004-04-20 JP JP2006513151A patent/JP4697973B2/ja not_active Expired - Fee Related
- 2004-04-20 AT AT04750364T patent/ATE450496T1/de not_active IP Right Cessation
- 2004-04-20 WO PCT/US2004/012142 patent/WO2004093806A2/en not_active Ceased
- 2004-04-20 CA CA2521589A patent/CA2521589C/en not_active Expired - Fee Related